Results 21 to 30 of about 1,876,096 (308)
Abstract Symptoms of unexplained exertional breathlessness or symptoms out of proportion to coexistent heart or lung disease should alert the clinician to the possibility of pulmonary hypertension, and the condition should be actively sought in patients with known associated conditions, such as scleroderma, hypoxic lung disease, liver ...
Benjamin, Hibbert+4 more
openaire +3 more sources
Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes ...
Georgios E. Papadopoulos+12 more
doaj +1 more source
Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [PDF]
On May 16 th , 2016, Nick H. Kim, MD [University of California San Diego (UCSD), Division of Pulmonary, Critical Care & Sleep Medicine] delivered his keynote presentation outlining the current state of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Anderson, Ryan J+2 more
openaire +5 more sources
Background The objective of this study was to assess, whether right atrial (RA) and ventricular (RV) size is related to RV pump function at rest and during exercise in patients with pulmonary arterial hypertension (PAH).
Lukas Fischer+12 more
doaj +1 more source
Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum+9 more
doaj +1 more source
Research questions Patients with severe pulmonary hypertension associated with chronic lung disease have a poor prognosis. Targeted pulmonary arterial hypertension therapies might improve exercise capacity and outcome, but there are no guidelines on ...
Romain Naud+10 more
doaj +1 more source
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
BACKGROUND Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes.
M. Humbert+17 more
semanticscholar +1 more source
Abstract We describe a case of fungal keratitis due to Beauveria bassiana in a farmer with Fuchs' dystrophy, treated with amphotericin B. Surgery with penetrating keratoplasty was necessary to resolve the lesions. Susceptibility testing and molecular sequencing permitted the identification and treatment of this rare aetiological agent of invasive ...
M. Ligozzi+8 more
wiley +1 more source
XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.
Chu Matsuda+16 more
wiley +1 more source
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
ACTRIIA-Fc, an activin and GDF8/11 ligand trap, improves hemodynamics and exerts antiremodeling effects in experimental pulmonary hypertension. Remedying pulmonary vascular remodeling Alterations in bone morphogenetic protein, growth and differentiation ...
L. Yung+20 more
semanticscholar +1 more source